(MENAFN- GlobeNewsWire - Nasdaq) The atrial fibrillation market thrives on rising disease prevalence, technological advancements in AI and remote monitoring, and the need for innovative treatments. Companies harnessing these technologies and forming strategic collaborations are poised for growth. Aging populations and risk factors like hypertension drive demand.Dublin, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Market Size, Share & Trends Analysis Report by Treatment Type (Pharmacological Treatment, Non-pharmacological Treatment), by End-use (Hospitals, Specialty Clinics), by Region, and Segment Forecasts, 2025-2033" report has been added to ResearchAndMarkets's offering.
The global atrial fibrillation market size was estimated at USD 26.89 billion in 2024 and is projected to reach USD 65.33 billion by 2033, growing at a CAGR of 10.44% from 2025 to 2033. The atrial fibrillation market is driven by a growing disease burden, rapid technological evolution in treatment and diagnostics, and the shift toward remote patient monitoring.
![]()
Companies capable of integrating these advancements into comprehensive care solutions are likely to lead market growth as clinical practices adapt to more efficient and patient-centric models. Strategic collaborations and acquisitions aimed at expanding access to innovative therapies will further accelerate market competitiveness.
The rising prevalence of atrial fibrillation, driven by aging populations and an increase in risk factors such as hypertension, diabetes, and obesity, is a major factor driving market growth. Atrial fibrillation is one of the leading causes of stroke and heart failure, prompting healthcare systems to prioritize early diagnosis and effective management. The growing patient pool is directly increasing demand for pharmacological treatments and advanced interventional procedures. In May 2024, the CDC highlighted atrial fibrillation (AFib) as the most common heart arrhythmia treated in the U.S. The number of Americans affected by AFib is expected to rise to 12.1 million by 2030. AFib plays a role in roughly 158,000 deaths each year and contributes to about 1 in 7 stroke cases.
Technological advancements in catheter ablation, 3D electro-anatomical mapping, and wearable ECG monitors are enhancing the precision and safety of atrial fibrillation treatments. Integration of artificial intelligence in arrhythmia detection and procedural planning is enabling faster, more accurate diagnosis and targeted therapy. These innovations are expanding treatment options to more patients while improving procedural outcomes and reducing recurrence rates.
In April 2025, according to the Heart Rhythm Society (HRS), new research unveiled at Heart Rhythm 2025 showcased how artificial intelligence (AI) is enhancing safety and success rates in atrial fibrillation (AFib) treatments. The AI-driven DeePRISM model enables real-time waveform analysis during ablation procedures, improving outcomes for patients with persistent AFib. Experts highlighted AI's potential to transform electrophysiology by boosting clinical confidence and procedural precision.
The adoption of remote monitoring and telehealth platforms is changing how atrial fibrillation is managed, allowing continuous rhythm monitoring beyond clinical settings. Wearable ECG devices and smartphone-linked applications are providing real-time data to both patients and physicians, supporting proactive management and early intervention. Healthcare providers are leveraging these tools to monitor larger patient populations efficiently, especially for post-procedural follow-up and long-term care. In May 2025, researchers from the Melbourne Brain Centre developed an AI model that can detect silent atrial fibrillation (AF) in stroke patients by analyzing brain MRI scans. The technology showed promising accuracy (AUC 0.81) in differentiating AF-related strokes, offering a non-invasive and efficient detection method. This approach could potentially accelerate diagnosis and personalize stroke care by flagging hidden AF cases needing further cardiac evaluation.
The clustered column chart highlights the incremental rise in atrial fibrillation-related disability-adjusted life years (DALYs) and death rates across the Americas from 1990 to 2021. DALYs increased from 117.14 to 120.68 per 100,000 and death rates rose from 4.18 to 4.84 per 100,000. This reflects a persistent and growing burden on healthcare systems, particularly in regions where access to early detection and advanced treatment remains uneven. Without targeted healthcare policies to bridge these regional disparities, the clinical and economic strain of atrial fibrillation is projected to intensify in the coming decades.
Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia worldwide, posing a substantial challenge to healthcare systems due to its association with stroke, heart failure, and elevated mortality risks. Despite advancements in treatment options, the global prevalence of AF has more than doubled over the past three decades, driven by aging populations and lifestyle-related risk factors. In July 2025, according to The Lancet Regional Health Americas, regional disparities continue to shape the burden of atrial fibrillation across the continent. The U.S. experienced the highest rise in AF incidence and prevalence, while Canada saw a decline after age adjustments. Middle-income countries account for the majority of AF cases, facing rising incidence rates with limited screening infrastructure. Addressing these systemic gaps is critical to mitigating AF's escalating clinical and economic impact in the region.
Why should you buy this report?
Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
Market intelligence to enable effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Segmental and regional revenue forecasts for market assessment Competition strategy and market share analysis Product innovation listings for you to stay ahead of the curve COVID-19's impact and how to sustain in these fast-evolving markets
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 150 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value (USD) in 2024 | $26.89 Billion |
| Forecasted Market Value (USD) by 2033 | $65.33 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
Global Atrial Fibrillation Market Variables, Trends & Scope
Market Lineage Outlook Parent market outlook Ancillary market outlook Market Dynamics Market driver analysis Market restraint analysis Global Atrial Fibrillation: Market Analysis Tools Industry Analysis - Porter's PESTLE Analysis Technology Landscape Case Study Analysis
Companies Featured
AtriCure Inc. Boehringer Ingelheim GmbH Boston Scientific Corporation Bristol- Myers Squibb Corporation Cardio Focus Inc. Sanofi Aventis Biosense Webster Inc. Endoscopic Technologies Inc. Abbott (St. Jude Medical Inc.) Johnsons & Johnson
Global Atrial Fibrillation Market Report Segmentation
Treatment Type Outlook (Revenue, USD Million, 2021-2033)
Pharmacological Treatment Anti-arrhythmic Drugs Anticoagulant Drugs Non-Pharmacological Treatment Catheter Ablation Radiofrequency HIFU Cryoablation Microwave Laser Maze Surgery Electric Cardioversion
End-Use Outlook (Revenue, USD Million, 2021-2033)
Hospitals Specialty Clinics Others
Regional Outlook (Revenue, USD Million, 2021-2033)
North America U.S. Canada Mexico Europe U.K. Germany France Italy Spain Denmark Sweden Norway Asia-Pacific Japan China India South Korea Australia Thailand Latin America Brazil Argentina Middle East & Africa South Africa Saudi Arabia UAE Kuwait
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Atrial Fibrillation Market
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
![]()
MENAFN26092025004107003653ID1110115724
Comments
No comment